UCN-01 blocks PKC activity (IC50 4.1 nM) by binding to its catalytic domain [135] with significantly higher affinity for conventional (c) PKC than for novel (n) PKC and atypical (a) PKC [136], disturbing the transition from the G1 to S phase, thus preventing cancer cell growth [137]. Here, PRRT2 is linked to cancer.